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A systematic and ordered product development program, in compliance with current
quality and regulatory standards, increases the likelihood of yielding a successful
advanced therapy medicinal product (ATMP) for clinical use as safe and effective therapy.
As this is a novel field, little accurate information is available regarding the steps to be
followed, and the information to be produced to support the development and use of
an ATMP. Notably, successful clinical translation can be somewhat cumbersome for
academic researchers. In this article, we have provided a summary of the available
information, supported by our experience in Spain throughout the development of an
ATMP for myocardial infarction, from the pre-clinical stage to phase I clinical trial approval.
Keywords: advanced therapy medicinal product, investigational medicinal product, investigational medicinal
product dossier (IMPD), translational (regulation), regulatory agency
INTRODUCTION
Recent years have brought tremendous developments in cardiac tissue engineering (1). Cell therapy
approaches have been attempted for the repair of scars left by myocardial infarction (MI); however,
clinical trials have reported only modest and clinically irrelevant improvements in cardiac function
(2–4). Thus, the research focus has shifted to cardiac tissue engineering approaches that can deliver
cells to the injured myocardium with supportive scaffolds, thus improving cell retention and
survival (5). Successful clinical translation of these engineered constructs requires that specific steps
be followed from scientific, quality, and regulatory standpoints. First, they have to be conceived and
developed in a basic research laboratory. Second, they need to be confirmed as safe and effective
in relevant animal models. Third, they must be adapted to current good manufacturing practice
(GMP)-compliant procedures for obtaining an advanced therapy medicinal product (ATMP).
Finally, the ATMP has to be tested in patients in the context of a clinical trial.
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SECTIONS ON ASSESSMENT OF
POLICY/GUIDELINES OPTIONS AND
IMPLICATIONS
In 2003, the concept of ATMP was defined and introduced in
European legislation. ATMP originally comprised gene therapy
medicinal products (GTMPs) and somatic cell therapy medicinal
products (CTMPs), with the later inclusion of tissue-engineered
products (TEPs) in Regulation (EC) No. 1394/2007 (6, 7). The
ATMP industry is still emerging, and many therapy proposals in
this field are led by independent researchers who have little, if
any, process development experience (8).
ATMPs are ground-breaking medicines based on the use
of genes, tissues, or cells for the treatment of human disease
and injury. They are classified into four main types: GTMPs,
CTMPs, TEPs, and combined ATMPs. GTMPs contain genes
that have therapeutic, prophylactic, or diagnostic effects. CTMPs
include cells or tissues that have been substantially manipulated
to change their biological characteristics, physiological functions,
or structural properties, or that are intented to be used for a
purpose other than their essential functions in the body, with
the aim of treating, preventing, or diagnosing a disease. TEPs
contain modified cells or tissues of human and/or animal origin
(viable or non-viable) that are used to repair, regenerate, or
replace human tissue (9). Finally, combined ATMPs contain a
medical device as an integral part of the product (10). They
may also contain additional substances, such as biomaterials,
chemicals, scaffolds, or matrices. The mechanisms of action of
ATMPs include pharmacological, immunological, or metabolic
activities (10).
Due to the novelty and complexity of ATMPs, there is a
lack of accurate information regarding the steps required for
their clinical translation, and data that must be produced to
achieve regulatory agency approval. This can make it difficult
for independent researchers from an academic environment
to successfully get an ATMP to the patient population.
Investigational medicinal product (IMP) development can be
challenging in many aspects, including materializing a research
idea, cell/tissue isolation and characterization, preclinical studies
to prove safety and efficacy, scaling-up prototypes for human use,
defining manufacturing processes in accordance with current
GMP, and meeting all ethics and regulatory requirements
(10–14). Our group recently developed a pioneering ATMP,
named PeriCord, that is presently being tested in humans
for cardiac repair after MI. PeriCord comprises a human
decellularized pericardial matrix enriched with Wharton’s jelly-
derived mesenchymal stromal cells (15). Here, we report our
experience in creating this IMP in Spain, and through its
translation from preclinical stages to use in patients (15).
Abbreviations: AEMPS, Spanish Agency of Medicines and Medical Devices;
AEMPS, Agencia Española del Medicamento y Producto Sanitario; ATMP,
Advanced Therapy Medicinal Product; MTA, Medicamento de Terapia Avanzada;
CTD, Common Technical Document; IMP, Investigational Medicinal Product;
PEI, Producto En fase de Investigación; IMPD, Investigational Medicinal Product
Dossier; EPEI, Expediente de Producto En fase de Investigación; TPP, Target
Product Profile; FDP, Ficha de Desarrollo del Producto.
Four Stages Along the Journey
Preclinical Stage
Basic research laboratories can generate regenerative/repair-
driven hypotheses and test them in animal models. To achieve
clinical translation, a newly developedATMPmust be proven safe
and effective in a planned preclinical program including studies
addressing pharmacodynamics (PD), pharmacokinetic (PK), and
toxicology (Tox) (16, 17). For a product to be proven safe, the
risk-benefit profile must be assessed as acceptable for the target
disease or condition, the product must be well-characterized to
reduce batch variability and ensure the expected function, and
the genetic stabilitymust be confirmed. Accurate characterization
of the product is also important for avoiding differences in
effectivity, ensuring consistency from dose to dose (11). Thus, as
soon as possible, it is important to define the identity, viability,
purity, and potency of the ATMP.
Experiments in animal models should be conducted to
evaluate the biodistribution of an ATMP in principal organs
(e.g., brain, liver, spleen, lungs, kidneys, and gonads), to identify
target organs and tissues (18), and to assess local effects. Studies
must review and confirm the expected mechanism of action
of the product’s active ingredient, i.e., the biologically active
ingredient that exerts the expected therapeutic effect. Animal
experiments should also reveal an absence of tumorigenic activity
and an acceptable safety profile. In terms of effectiveness, animal
models may prove efficacy by confirming the hypothesis at the
preclinical level. In some cases, no animal model is available
for the specific pathology under investigation. In this case, a
new model can be designed if the basic research group has
sufficient experience in the pre-clinical large animal setting, and
can fine-tune a model to mimic a human pathological scenario.
However, sometimes a disease cannot be reproduced due to its
high complexity or mortality. In this scenario, pre-clinical studies
can be performed using different animal models that present the
different symptoms separately.
Prior to administration to a patient, the product must comply
with the above-described requirements, as well as others.
Translational Stage
We refer as the translational stage, the phase during which the
researchers have a proof of concept and are ready to start working
to develop a product for clinical use. Several considerations must
be taken into account for products intended for human use:
1. The preclinical product must be adapted to fulfill the
regulatory and legal requirements for human use. To this
end, the ATMP must be manufactured following procedures
in compliance with current GMP standards and in GMP-
accredited facilities. If the preclinical product was not
originally produced using GMP procedures and/or clinical
grade reagents, it should be modified. Due to the potential
impact on the final product’s safety and quality, ATMP
developers must make available the quality attributes and
composition of all raw materials used in the manufacturing
process. Importantly, this information is required for
the regulatory submission, especially when animal-derived
components are used. Any raw materials and excipients
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must be suitable for clinical use, and some may have to
be substituted for others with similar characteristics upon
appropriate risk analysis and experimental testing (e.g.,
xeno-free, clinical grade ingredients) (19), which may be
more expensive. Additionally, sometimes extensive ex vivo
expansion is required to yield sufficient cell numbers for
clinical use, and scale-up processes should be defined and
incorporated within the manufacturing procedure to adapt
doses and/or final product dimensions to human scale (20).
2. For autologous cell products, “scaling-out” usually requires
the ability to conduct multiple parallel bioprocesses by
using traditional planar 2D cultures for the production
of larger amounts of finished product (20, 21). For
unmatched allogeneic products, “scaling-up” involves
the use of expansion platforms, such as bioreactors, to
entail reproducible and robust manufacturing bioprocess,
therefore offering major advantages with respect to
GMP implementation.
Some specific documents must be generated to collect all of
the information required by the competent authorities for their
evaluation and approval of the IMP, and their approval of a
clinical trial together with the local ethics committee. These
aspects will be detailed in the section ATMP approval for
clinical trials.
Production Stage
Several issues must be addressed prior to the actual production of
an ATMP.
1. GMP compliance: The ATMP manufacturing facilities must
comply with current GMP, thus guaranteeing the quality and
safety of the manufactured products. This accreditation is
granted by the competent authorities, e.g., the AEMPS in
Spain. GMP is a quality management system to ensure that
products are consistently processed and controlled according
to quality standards. This system guarantees traceability
at all times, covering every aspect of manufacturing and
distribution. GMP covers all aspects of production, from
the starting materials, premises, and equipment to staff
training and personal hygiene. It is essential to have detailed
written procedures (standard operating procedures; SOP) for
each process that could affect the finished product quality,
which are followed each time a product is manufactured
(22). Quality control documents are required to register
all utilized processes and materials, including batch records
and expiration dates. The products commonly used in
preclinical studies are often unsuitable for clinical use. For
some such ingredients, excipients, or culture reagents, there
is an equivalent, generally more expensive, GMP-compliant
alternative. However, other materials may be more difficult to
replace. For example, bovine serum has been widely used in
cell culture for over a century (23), but the current trend is to
switch from the use of serum or platelet lysate to serum-free
chemically defined media formulations to alleviate concerns
regarding safety (i.e., xenoviral transfer and contamination),
efficacy (batch-to-batch variation), and scarcity (11, 20, 23).
2. Reproducibility, safety, and consistency: There are several
critical process stages for assuring consistency andmeeting the
established specifications of the finished drug product (DP)—
including tissue harvesting, cell isolation and expansion,
cell and finished product storage, lot size (number of cells
per production batch), and methods. The manufacturing
bioprocess is designed to minimize the risks of deviating
from specifications along the production process, such that
there is no need to solely rely on testing of the finished
product. This is known as “quality by design (QbD),” an
approach that aims to ensure product quality by combining
statistical, analytical, and risk-management methodologies
into the design, development, and manufacturing processes
(24–26). Acceptance and release criteria must be determined
to ensure the safety and consistency of the final DP,
with regards to microbiological growth (negative serological
and microbiological testing), physiochemical properties,
dose range, cell viability, and endotoxin levels, among
other concerns.
3. Scalability: Process scalability is a major factor to consider
when starting from a preclinical product and aiming to
develop its corresponding IMP format. For translational
allogeneic cell therapy that requires cells, reagents, and culture
media, large numbers of cells are needed to achieve a
certain dose ready for use in several patients, thus affecting
product cost and quality (17). The cells must retain their
key quality attributes of identity, potency, purity, and safety,
and there must be no changes in quality with regards to cell
differentiation capability (11). Quality by design strategies and
classical experimental design approaches can be applied to
optimize cell culture media, reagents, and process parameters
to create a robust, reproducible, and scalable process (11, 27).
4. Stability: The DP stability period must be determined based
on cell stability and the product life cycle (28). Cells can
multiply, but do not have to multiply continuously, only when
needed for their normal cycle. When they multiply, they must
maintain a stable karyotype and stable expression of cytokine
markers and telomerase. The product life cycle is the process
a product goes through once it is released until it is removed
upon reaching its expiration date. This shelf-life is determined
based on changes in the product characteristics, and is assessed
in the preclinical stage and during product development, and
might be reassessed during the clinical trial phase according to
the product stability protocols.
All of these factors must be considered tomanufacture a clinically
appropriate product adapted from the preclinical version. The
end results must be a comparable product in terms of identity,
purity, potency, and safety (29).
ATMP Approval for Clinical Trials
After the preclinical and translational stages, and upon achieving
ATMP manufacturing and validation, all required information
must be presented to the competent authority and final approval
obtained to commence a clinical trial. Here we summarize all
of the documentation required for presentation to the Spanish
Agency of Medicines and Medical Devices (AEMPS):
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1. Target Product Profile (TPP): This is not a mandatory
document in Spain, but rather a summary of the necessary
information about the product development process. A TPP
is created with the aim of ensuring that the drug development
process is efficient and provides all of the required medical,
technical, and scientific information about a product (30). It
can be worthwhile to start the TPP at an early stage (preclinical
stage) to provide a clear vision of the whole process.
2. Investigational Medicinal Product Dossier (IMPD): The
IMPD, including modules 1 to 5 (described below), is one
of the main IMP-related documents required for clinical trial
approval in one or more European Union Member States.
The IMPD includes regional administrative information and
summaries of the data related to the quality, manufacture, and
control of any IMP (including both reference product and
placebo), as well as data from non-clinical and clinical studies
(Figure 1).
The AEMPS does not offer guidance on writing an IMPD, but
suggests following the European Guidance from the European
Medicines Agency (EMA) (31). Figure 1 shows the parts of the
IMPD as summarized in a Notice to Applicants (32) prepared
by the European Commission in consultation with competent
authorities of the member states, the EMA, and other interested
parties as a guideline for fulfilling the obligations raised by Article
6 of Regulation (EC) No. 726/2004, and with respect to Annex
I of Directive 2001/83/EC (European Commission Notice to
Applicants). Based on this Notice to Applicants, we adapted the
index for our IMP, as shown in Table 1.
The IMPD includes the following modules:
- Module 1: This section is not a part of the Common Technical
Document (CTD), and includes all regional administrative
information required by the AEMPS.
- Module 2: This module provides an overview of all of the
information, divided into several sections, including a table
of contents (2.1), introduction (2.2), review of the quality
information (2.3), review of the non-clinical data (2.4), review
of the clinical data (2.5), and two tabulated summaries: one for
the non-clinical data (2.6) and one for the clinical data (2.7).
- Module 3: This section is a compendium of the available
quality information, which will also be sent as a discrete
document in Block I of the required documentation for
the Ethics Committee and AEMPS evaluation (see below).
The document includes data regarding the characterization,
fabrication, specifications, stability, packaging, and quality
control analysis of the active ingredient and the finished
product (i.e., the ATMP).
- Module 4: This module constitutes a compendium of the
available non-clinical data, which includes toxicity and
biodistribution studies, mechanism of action, and safety data.
For TEPs, this includes information concerning the genetic
stability of the active cells, and in vivo efficacy studies.
- Module 5: This non-compulsory module includes clinical
study reports, when available.
This structure indicates the necessary experiments for gathering
all of the required data in terms of quality and fabrication
FIGURE 1 | Parts of the Investigational Medicinal Product Dossier (IMPD) as
collected in the Notice to Applicants prepared by the European Commission.
(Module 2, section Quality overall summary, and Module
3), as well as the pharmacological mechanism of action,
pharmacokinetics, toxicity, biodistribution, and safety (Module
4). The IMPD serves as an excellent tool for defining all
necessary preclinical studies, and for aligning manufacturing
process requirements with product specifications (11).
3. Common Technical Document (CTD): The International
Council for Harmonization of Technical Requirements for
Pharmaceuticals for Human Use (ICH) has the mission of
bringing together regulatory authorities and pharmaceutical
industries worldwide to ensure that safe, effective, and high-
quality medicines are developed and registered in the most
resource-efficient manner (33). Toward this aim, they created
a common format, the CTD (Figure 1), to gather information
regarding quality, safety, and efficacy. Module 1 is region-
specific, while Modules 2, 3, 4, and 5 are intended to be
common among all regions—as has beenmandatory since July
2003 in the EU and Japan, and is the strongly recommended
format of choice in the United States.
4. Protocol: The protocol describes how the clinical trial will
be conducted, and is the most important document for
clinical trial execution. The protocol must include a title;
a protocol number, version number, and date; the study
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TABLE 1 | Investigational medicinal product dossier (IMPD) index adapted from the Notice to applicants by the European Commission.
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2.7. Written and Tabulated Clinical Summaries
2.7.1 Biopharmaceutical studies and related
analytical methods
2.7.2 Clinical pharmacology studies
2.7.3 Clinical efficacy studies
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4.3. MSCs Toxicity and Biodistribution Studies
4.3.1. Intrathecal and systemic administration of
MSCs, WJ in an immunodeficient murine
model of traumatic spinal cord injury
4.3.2. Administration of MSCs carried through
fibrin matrix in an immunodeficient murine
myocardial infarction model
4.4. Multipotency oF MSC,WJ
4.5. Immunomodulation Studies
4.6. Genetic Stability of MSC,WJ
4.7. In vivo Efficacy Studies
4.7.1. Efficacy study of the implantation of
MSCs carried by matrices in the murine
myocardial infarction model
4.7.2. Efficacy study of the implantation of
MSCs carried by matrices in the porcine
myocardial infarction model
4.8. References
objective and justification, containing all relevant previous
clinical and preclinical data; the study design; candidate
inclusion and exclusion criteria; intervention or treatment;
risks and benefits, including adverse reaction definition and
reporting; expected trial start and end dates; study withdrawal
and blind-opening, if applicable; data management, and
statistical analysis; ethical and regulatory considerations;
document archive and font documents; quality control;
funding; publication policy; references; and annexes. It is
highly recommended that this document include a figure
explaining the study design and a table detailing the scheduled
study visits.
5. Informed consent form: Informed consent is the procedure
guaranteeing that a subject gives consent to participate
in a research study, having and understanding all of the
information related to the trial objectives, its possible benefits,
the risks and inconveniences, the available alternatives, and
his/her rights and responsibilities. The candidate subject must
have time to think and ask any necessary questions. All of
the provided information must be collected in a document
with a version number updated with current legislation, and
two printed copies must be signed, dated, and kept by the
investigator and the patient.
6. Investigator’s Brochure (IB): This document is addressed to
the researchers involved in the trial, providing a compilation
of the clinical and non-clinical data regarding the product,
and the reference safety information. The IB includes all of the
IMP-related information from the IMPD that the investigator
will need to correctly manage the IMP and the included
subjects, ensuring their understanding of the study rationale,
IMP dose, dose range, administration, and safety monitoring
parameters. The IB should include a title page; summary;
table of contents; introduction; section describing the
product’s physical, chemical, and pharmaceutical properties;
non-clinical studies (pharmacology pharmacokinetics, and
toxicology); effects in humans (pharmacokinetics, safety,
and efficacy); and a summary for the investigator. If an
event that is not listed in this document occurs during
the trial, the investigator must consider it a non-expected
adverse event, and must notate it as such. The contents are
detailed in the guideline EMA/CHMP/ICH/135/1995
and the required information is obtained from the
IMPD (34).
Competent Authorities Involved
National Level: Competent Authority
Correspondence, Approval Request, and Clinical Trial
Registration
The AEMPS is the national regulatory agency in Spain. There
are several different ways of corresponding with the AEMPS.
First, for preliminary specific questions related to the proposed
study, enquiry e-mails can be sent to the Support Office
for Independent Clinical Research, Clinical Trials Division,
Pharmaceutical Medicines for Human Use Department.
Second, in the early stages, when considering moving
toward the clinical phase, scientific advice can be sought.
Scientific advice meetings are face-to-face sessions at AEMPS
facilities, at which researchers present their intentions and
the questions that they want to discuss with experts from
the regulatory agency. These professionals act as assessors
for the investigational team, and include representatives from
different areas, such as the Division of Biological Products,
Advanced Therapies and Biotechnology, and Department of
Medical Devices. After the meeting, correspondence occurs
between the experts and the Quality Research Department,
Pharmacology and Clinical Assessment Division, Medicines
for Human Use Department, to whom minutes of the
meeting must be sent. Figure 2 presents a template for
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FIGURE 2 | Template to write minutes after obtaining scientific advice from the Spanish Agency of Medicines and Medical Devices (AEMPS).
summarizing meeting minutes. This document is revised and
accepted by the AEMPS, and will be part of the collected
documentation required to obtain regulatory approval for the
clinical trial.
Third, the documentation is submitted via the AEMPS
platform (https://ecm.aemps.es/). Figure 3 shows the list of
documents that must be uploaded to the platform (35). The
evaluation is separated into two main blocks. Block I includes the
documents that must be sent to the AEMPS and to the local ethics
committee. Block II comprises documents to be sent exclusively
for local ethics committee evaluation. The AEMPS must validate
Block I, and the local ethics committee must validate Blocks I and
II within a maximum of 10 natural days (Figure 4) (36). Both
organizations can request rectifications and/or clarifications and
the process can be extended over time. Upon approval by the
AEMPS and the local ethics committee, the clinical trial must be
publicly registered in the Spanish Clinical Trial Registry (REEC,
from Registro Español de Estudios Clínicos; https://reec.aemps.
es/).
European Level: EMA Communication and EU
Clinical Trials Registry
The European Regulation on ATMPs has introduced a
classification procedure that gives developers the opportunity
to verify whether their product can be considered an ATMP.
This procedure is optional, free of charge, and may occur at any
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FIGURE 3 | List of documents to upload to the Spanish Agency of Medicines and Medical Devices (AEMPS) platform for investigational medicinal product (IMP)
approval.
FIGURE 4 | Due dates after Spanish Agency of Medicines and Medical Devices (AEMPS) document submission.
stage of ATMP development prior to applying for marketing
authorization. There is also the possibility of briefing meetings
for preparing ATMP classification, which are organized by the
EMA Innovation Task Force and represent a starting point
for interactions between the European agency and the ATMP
developers (6), enabling the EMA to provide scientific advice.
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FIGURE 5 | Process of clinical translation.
However, AEMPS decisions are harmonized with decision by the
EMA, and it is not necessary to seek both.
After local regulatory approval, the clinical trial should be
registered in the European clinical trials database (EudraCT,
https://eudract.ema.europa.eu/eudract-web/index.faces) to allow
public consultation of updated study-related information.
DISCUSSION
Our group is a multidisciplinary team—including basic
researchers (biologists, biochemists, and veterinarians) and
clinical researchers (physicians and pharmacists). This diversity
may not be common in basic research groups, which may need
to look outside of their group for a clinical perspective early
in the translation process. Notably, despite being a quite large
multidisciplinary group, we still had to seek a partner with broad
experience in production and product quality. This is why we
created a consortium with a center that had the knowledge
that we were lacking, had GMP procedures established in their
daily activity, and possessed all of the facilities needed for
product production.
We had studied cardiac regeneration as a basic research group
for almost 10 years. Then we spent over a year to adapt our
product and our processes to GMP and, together with our
partner center, we generated the IMPD. The optimum approach
is to start planning the full process from the very beginning,
when a research idea is generated, with the involvement of
all experts. Considering the development of an investigational
product as a project enables early planning of a scheme that
includes preclinical and in-vivo animal models and quality
aspects, along with bioprocess aspects, as well as compliance
with the GMP and legal framework requirements (16). This
approach is important to ensure appropriate design of the
non-clinical package required for a clinical trial—helping to
avoid skipping process steps; setting overly optimistic deadlines;
underestimating the financial, time, and personnel requirements;
and performing studies without proper documentation (16).
Figure 5 depicts the whole process for clinical translation. We
performed a lot of work without having considered all GMP
requirements, which resulted in a longer overall process. We are
now aware of these issues for future projects that we hope to be
developing together as a consortium.
In conclusion, basic research laboratories can generate
innovative regenerative/repair-driven hypotheses; however,
preclinical products must go through a complex process of
translational adaptation before reaching patients. Intentions
should be discussed with the competent authorities as early
as possible, as they may guide researchers to avoid possible
errant pathways that would result in great losses of time and
money. When intending to assess an ATMP in a clinical trial, the
IMPD is the most complex and important document to develop.
Its structure provides researchers with guidance regarding
the preclinical data needed to generate a safe and effective
IMP. Key steps along the process include scalability and GMP
manufacturing, along with animal models to perform PD, PK,
and Tox studies.
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